BRIEF: Lufax replaces chief risk officer

6623.HK
LU.US
Nanhua does finance

Online lender Lufax Holding Ltd. (LU.US; 6623.HK) on Friday announced that Youn Jeong Lim resigned as the company’s chief risk officer, citing “personal work arrangements, and was replaced by Cheng Jianbo, effective Oct. 24. Before joining Lufax in April this year, Cheng’s previous employers included e-commerce giant JD.com, Ping An Bank and Ant Group, the financial affiliate of Alibaba.

Lufax’s U.S.-listed shares rose 2.8% on Friday after the announcement, and are up 38% this year. Its Hong Kong-listed shares have been suspended since January following a dispute with its auditor at that time.

The company said in July it has hired a new auditor, Ernst & Young, fulfilling a necessary step before it can resume filing new financial reports. It has yet to publish official quarterly results since the third quarter of last year. But in a July business update it said the balance of its total outstanding loan volume at the end of June stood at 193.4 billion yuan ($27 billion), down 17.8% from a year earlier.

By Doug Young

To subscribe to Bamboo Works free weekly newsletter, click here

,
,

Related Articles

RELATED ARTICLES

  1. Lufax provides loans
    Lufax deepens Ping An reliance, as it works towards trading resumption
    6623.HK
    LU.US
  2. BYD supplier Cheng-Tech bets on budget option for assisted driving
  3. Shenyang city ups offer for Shengjing Bank to end its misery as a listed company
    2066.HK
  4. With so many new IPOs, Quantgroup looks better left for high-risk investors
  5. Honor IPO advances, as new chief talks up its AI credentials
  6. Shandong Hi-Speed stock soars, then plunges in mystery power play
    0412.HK
  7. Work in progress: East Buy reinvents itself – again
    1797.HK
Discover hidden China stock gems in our weekly newsletter

Follow us

Facebook Twitter Linkedin Weixin Weibo Youtube

Subscribe to Our Free eNewsletter

Subscribe

Check out our content with some of our syndication partners

factiva

Recent Articles

Geneplus IPO

Geneplus locks onto targeted medicine for IPO pitch

After a post-Covid earnings dip, the company is seeking a stable future as a provider of data and diagnostics for precision medicine and disease prevention   Key Takeaways: The company’s…

Hong Kong’s IPO rally under scrutiny, as ZTE hits new U.S. headwinds

Hong Kong's stock regulator has warned IPO underwriters over the declining qualiy of new listing applications. Is this a red flag for the city's booming IPO market, or just the usual regulatory caution? And the U.S. could fine telecoms equipment maker ZTE $1 billion for bribery in Brazil. Why does Washington think it can force ZTE to pay such a large amount?